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Abstract
In this retrospective study, 36 patients were given oxymetazoline
as a first step in treatment forposterior epistaxis. In 75% of the cases,
epistaxis was effectively treated with oxymetazoline with no recur
rent bleeding. All cases with recurrence resolved with continued
administration of oxymetazoline. The results of this study propose
a pharmacologic intervention for the treatment of posterior epistaxis.
Introduction
Epidemiology
About 60% of the western population will experience at least one
episode of epistaxis during their lifetime.’ According to Josephson,2
15 per 10,000 persons require attention by a physician for epistaxis
annually, and of the 15, 1.6 persons will require hospitalization.
The cause of epistaxis is often obscure, and the patient often is
unable to recall the precipitating factor. However, desiccation from
dry air with resulting mucosal wall cracking, nose picking, or hard
nose blowing are the most common causes of anterior nose bleeds,
whereas systemic disease almost always manifest themselves as
posterior bleeds.3Table 1 lists local and systemic causes ofepistaxis.
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Sites of bleeding
Anterior epistaxis almost always originates from Kiesselbach’ s
plexus, but can also occur from the branches of the sphenopalatine
artery. It is more common in persons under 40 years of age, and
usually a result from trauma.’
Posterior epistaxis originates most commonly from the sphenopa
latine artery as it emerges from behind the inferior and middle
turbinates. It accounts for 5-10% of all cases of epistaxis and is more
common in persons over 40 years of age.’ Posterior epistaxis is
usually associated with systemic disease.
Treatment
Pinching the nose for 10-15 minutes locally controls anterior
epistaxis. For recalcitrant bleeding, suctioning, with silver nitrate
cauterization is performed. For posterior epistaxis, it is difficult to
visually locate the site of hemorrhage due to the anatomy of the
posterior part of the nose and because posterior nosebleeds are
usually profuse. Local packing has therefore been the traditional
approach to control hemorrhage. Cut-down tampons, inflated
trimmed Foley catheters, nasal tampon balloons, or Merocel have
been utilized. The disadvantage of posterior packing is that they
require hospital admission for observation of possible complica
tions (Table 2.). Other methods of treatment include electrocautery,
ligation surgery, arterial embolization and cryotherapy.
Oxymetazoline Hydrochloride
Oxymetazoline is a topical decongestant, which acts as a local
vasoconstrictor of intermediate duration. We believe that the vaso
constrictive effects of oxymetazoline can be applied to arresting
nosebleeds. Krempl and Noorily demonstrated that the use of
oxymetazoline alone was sufficient to control 65% of cases of both
anterior and posterior epistaxis presented to an emergency center
[4]. In addition to the ease of administration, other factors which
make oxymetazoline attractive are cost (average cost less than
$500), avoidance of hospitalization, and avoidance of uncomfort
able procedures for the patient.
Table 1.— Etiology of Epistaxis
Local Systemic
Nasal of facial trauma
Upper respiratory tract infections
Nose picking
Allergies
Low home humidity
Nasal polyps
Foreign body
Environmental irritants
Nasopharyngeal neoplasm
Traumatic internal carotid aneurysm
Postoperative bleed
Table 2.— Complications of Local Posterior PackingAtherosclerosis of nasal blood vesselsHypertension
Diabetes Mellitus
Anticoagulant therapy
Abrupt changes in barometric pressure
Pregnancy
Chemotherapy
Blood dyscrasias
Hereditary hemorrhagic telangiectasis
Folic acid deficiency
Alcoholism
Chronic nephritis
Migraine headache
Acute febrile illness
Hypoxemia
Sepsis
Esophageal perforation
Hemotympanum
Middle ear effusion
Acute otitis media
Acute sinusitis
Ruptured tampon balloon with aspiration of saline
Necrosis of mucous membranes
Pressure necrosis of skin
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Materials and Methods Table 3.— ResultsIn this study, 532 cases of epistaxis were reviewed from the office
of an Otolaryngology specialist from January 1, 1991 to August 30,
1996. Only adults with active posterior nosebleeds were included in
the study. Cases with mild epistaxis due to allergies or sinusitis were
not included in the study as these patients were treated with corticos
teroid inhalers, antihistamines, and/or antibiotics. Data regarding
age, sex, etiology, risk factors, treatment, follow up, and hospitaliza
tion were collected. Recurrence of epistaxis was recorded if there
was any evidence of active bleeding, which included trace amounts
within 6 months.
Four to six sprays of oxymetazoline in each nostril were given as
a first step in treatment. Patients were then instructed to remain in a
sitting position and rest quietly. Patients were observed for one to
two hours, and readrninistration of oxymetazoline was done if
bleeding persisted. After severe bleeding stopped, the patients were
sent home and instructed to continue oxymetazoline administration
at a dose of two sprays in affected side every 6 hours until returning
for follow up assessment within one to three days.
Results (Tables 3 and 4)
Of the 532 cases reviewed, 36 patients were selected for this
retrospective study. All data regarding gender, age, risk factors and
etiology is presented in table 3. There was a good distribution among
men and women, 17 verses 19 respectively. Average age for patients
with posterior epistaxis was essentially the same for both men and
women (64 yrs for male, and 62 yrs for females.)
Of the risk factors included in the study, hypertension was present
in most patients (13; 36%), followed by acetylsalicylic acid use (6;
17%), diabetes mellitus (5; 14%), coumadin use (3; 8%), thromb
ocytopenia (2; 6%), and radiation therapy (2; 6%).
Twenty-eight patients (78%) did not have a causal history for
epistaxis. Trauma accounted for 4 cases (11%), and the remaining
etiologies accounted for one case each. One case of sinusitis was
included, because epistaxis was profuse, and was subsequently
treated with oxymetazoline.
Oxymetazoline was administered in all cases. Eight cases had
additional gel foam placement, not to be used as packing, but to
provide topical application of oxymetazoline. Recurrence occurred
in 9 patients (25%). Three patients were admitted to the hospital, 2
for blood transfusions, while the other was admitted due to his
preexisting history of congestive heart failure, atrial fibrillation and
hypertension in addition to blood loss. In all three admissions,
oxymetazoline was continued without posterior packing. In all
cases, bleeding stopped eventually stopped. All other cases of
recurrent epistaxis were mild bleeds, which eventually ceased after
continued oxymetazoline use.
The influence that risk factors had on outcome is depicted in table
4. Of the 21 cases with a history ofepistaxis, 6(29%) had recurrence,
whereas only 3 of the 15 cases (20%) with no history ofepistaxis had
recurrent nosebleed. Of the 13 cases with a history of hypertension,
7 (54%) had recurrence, whereas only 2 of 23 cases (9%) with no
history of hypertension had recurrence. Three of 5 cases (60%) with
a history of diabetes had recurrence, while only 6 of 31 cases (19%)
of non-diabetics did. Of the 6 cases with a history of acetylsalicylic
acid use, 2(33%) had recurrence, while 7 of 30 cases (23%) with no
acetylsalicylic acid use had recurrence.
Discussion
In this study, 8.5% of epistaxis cases were of posterior origin.
Though lower than the estimated occurrence of 10% reported by
Perretta,5some of the discrepancy can be accounted for by the fact
that mild nosebleeds associated with chronic sinusitis and allergies
were not included. In 78% of the cases, there was no causal history
for epistaxis. This is consistent with Petruson who found that in the
majority of cases, the cause was unknown.
Hypertension is a major risk factor for posterior epistaxis.57In this
study, 36% of the total cases have a positive history of hypertension,
and of this subgroup, 54% had recurrence. Of the nine cases with
recurrent bleed, 7 had hypertension and 3 were diabetics. It is
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Patients (nI % Patients
Male 17 47
Female 19 53
Age
20-39 5 14
40-59 11 31
60 20 56
Risk Factors
ASA 6 17
Coumadin 3 8
Hypertension 13 36
Diabetes Mellitus 5 14
Thrombocytopenia 2 6
Radiation Treatment 2 6
Etiology
Unknown 28 78
Trauma 4 11
Polyps 1 3
Infection 1 3
Sinusitis 1 3
Pregnancy 1 3
Efficacy
No Recurrent Bleeding 27 75
Recurrent Bleeding 9 25
Table 4.— Influence of Risk Factors on Recurrence
Risk Factor Patients (n) Recurrence (%)
Epistaxis
Yes 21 (6/21)29%
No 15 (3/15)20%
Hypertension
Yes 13 (7/13) 54%
No 23 (2/23) 9%
Diabetes Mellitus
Yes 5 (3/5) 60%
No 31 (6/31)19%
ASA use
Yes 6 (2/6) 33%
No 30 (7/30) 23%
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possible that pathological structural changes within the arteriole
wall associated with hypertension and diabetes may result in reduc
tion of the blood vessels’ ability to change diameter in response to
oxymetazoline administration. Nonetheless, care should be taken
with oxymetazoline therapy in this population as it may be contrain
dicated due to its sympathomimetic property. Six of 21 cases with
a positive history of previous epistaxis had recurrence, which may
suggest that oxymetazoline is not as effective in patients with
recurrent epistaxis. However, it more likely re-establishes the fact
that posterior epistaxis is mostly secondary to underlying systemic
disease, that will continue until that underlying cause is addressed.
In all cases with recurrent epistaxis, oxymetazoline was continued,
and all nosebleeds did eventually cease. There is the possibility that
the epistaxis could have spontaneously stopped independent of
treatment. This study falls short of not having a prospective random
ized placebo controlled study. Therefore, further investigations
using large randomized controlled trials are necessary.
Oxymetazoline offers a cost-effective method of treatment. Due
to the necessity of monitoring patients following posterior packing,
or the need for surgery, the majority of patients with posterior
epistaxis will be admitted to the hospital. Duration of inpatient care
can range from 1 to 36 days, with a mean stay of 5.5 days.3Cost can
range from $1,000 to over $20,000)I In sharp contrast, posterior
epistaxis can be treated on an outpatient basis with oxymetazoline
at cost of less than $5.00 per 15 ml, and spares the patient from the
discomfort associated with posterior packing. In addition to its low
cost, it is also easily administered and therefore an attractive first-
line therapy for posterior epistaxis.
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